Immuron (NASDAQ:IMRN – Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.16 and traded as low as $1.02. Immuron shares last traded at $1.0650, with a volume of 8,419 shares.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Immuron in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Immuron has an average rating of “Sell”.
View Our Latest Analysis on IMRN
Immuron Price Performance
Institutional Trading of Immuron
An institutional investor recently bought a new stake in Immuron stock. Citadel Advisors LLC acquired a new stake in shares of Immuron (NASDAQ:IMRN – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.29% of Immuron at the end of the most recent quarter. Institutional investors and hedge funds own 0.12% of the company’s stock.
Immuron Company Profile
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.
Recommended Stories
- Five stocks we like better than Immuron
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.
